查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413450

硬皮症診斷和治療市場：按診斷測試、藥物類型、治療和適應症分類 - 全球預測 2024-2030

Scleroderma Diagnostics & Therapeutics Market by Diagnostic Tests (Blood Tests, Imaging, Pulmonary Function Tests), Drug Type (Calcium Channel Blockers, Chelating Agents, Corticosteroids), Therapeutics, Indication - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年硬皮症診療市場規模為20.9億美元，2024年預計將達21.9億美元，2030年將達32億美元，複合年成長率為6.25%。

全球硬皮症診斷與治療市場

主要市場統計
基準年[2023] 20.9億美元
預測年份 [2024] 21.9億美元
預測年份 [2030] 32億美元
複合年成長率（%） 6.25%
硬皮症診斷與治療市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估硬皮症診斷和治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對硬皮症診斷和治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-硬皮症診斷與治療市場的市場規模和預測是多少？

2-在硬皮症診斷和治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-硬皮症診療市場的技術趨勢和法律規範是什麼？

4-硬皮症診斷和治療市場主要供應商的市場佔有率是多少？

5-進入硬皮症診療市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 硬皮症患者病率不斷增加，需要有效的診斷技術和治療
      • 提高對硬皮症的認知並重視硬皮症的早期診斷
      • 開發新藥和治療方法的臨床試驗數量增加
    • 抑制因素
      • 治療硬皮症的費用很高
    • 機會
      • 成像技術和生物標記識別等診斷技術的進步
      • 繼續研究以確定硬皮症的有效治療方案
    • 任務
      • 與治療硬皮症的藥物相關的副作用
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章硬皮症診斷與治療市場：依診斷測試

  • 驗血
  • 影像
    • 電腦斷層掃描
    • MRI
    • X光
  • 肺功能檢查
  • 皮膚切片檢查

第7章硬皮症診斷與治療市場：依藥物類型

  • 鈣離子通道阻斷劑
  • 螯合劑
  • 皮質類固醇
  • 內皮素受體促效劑
  • 免疫抑制劑
  • PDE-5抑制劑
  • 細胞週期蛋白類似物

第8章硬皮症診斷與治療市場：依治療分類

  • 生物療法
  • 基因治療
  • 肺纖維化的治療
  • 雷諾現象的治療
  • 幹細胞移植

第9章硬皮症診斷與治療市場：依適應症分類

  • 局部
  • 系統性的

第10章 北美、南美硬皮症診療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區硬皮症診斷與治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東、非洲硬皮症診療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第14章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • Antibodies Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bio-Rad Laboratories, Inc
    • Biogen Inc.
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd.
    • Galapagos NV
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc（GSK）
    • Merck & Co., Inc.
    • Myriad Genetics, Inc
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi Genzyme
    • Takeda Pharmaceutical Company Limited
    • The Bristol-Myers Squibb Company
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech plc.
  • 主要產品系列

第15章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-8E22B61932E7

[186 Pages Report] The Scleroderma Diagnostics & Therapeutics Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.19 billion in 2024, at a CAGR 6.25% to reach USD 3.20 billion by 2030.

Global Scleroderma Diagnostics & Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.19 billion
Forecast Year [2030] USD 3.20 billion
CAGR (%) 6.25%
Scleroderma Diagnostics & Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Scleroderma Diagnostics & Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Scleroderma Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Scleroderma Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Antibodies Inc., AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Inc, Biogen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Myriad Genetics, Inc, Novartis AG, PerkinElmer Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., and Trinity Biotech plc..

Market Segmentation & Coverage

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Tests
    • Blood Tests
    • Imaging
      • CT Scans
      • MRI
      • X-rays
    • Pulmonary Function Tests
    • Skin Biopsies
  • Drug Type
    • Calcium Channel Blockers
    • Chelating Agents
    • Corticosteroids
    • Endothelin Receptor Agonists
    • Immunosuppressive Agents
    • PDE-5 Inhibitors
    • Prostacyclin Analogues
  • Therapeutics
    • Biologic Therapies
    • Gene Therapy
    • Pulmonary Fibrosis Treatments
    • Raynaud's Phenomenon Management
    • Stem Cell Transplantation
  • Indication
    • Localized
    • Systemic
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Scleroderma Diagnostics & Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Scleroderma Diagnostics & Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Scleroderma Diagnostics & Therapeutics Market?

4. What is the market share of the leading vendors in the Scleroderma Diagnostics & Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Scleroderma Diagnostics & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Scleroderma Diagnostics & Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
      • 5.1.1.2. Growing awareness about scleroderma condition and emphasis on early diagnosis
      • 5.1.1.3. Rising number of clinical trials for the development of novel drugs and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with scleroderma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
      • 5.1.3.2. Ongoing research for identifying efficient treatment options for scleroderma
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the drugs used in scleroderma treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Scleroderma Diagnostics & Therapeutics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Blood Tests
  • 6.3. Imaging
    • 6.4.1. CT Scans
    • 6.4.2. MRI
    • 6.4.3. X-rays
  • 6.4. Pulmonary Function Tests
  • 6.5. Skin Biopsies

7. Scleroderma Diagnostics & Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Calcium Channel Blockers
  • 7.3. Chelating Agents
  • 7.4. Corticosteroids
  • 7.5. Endothelin Receptor Agonists
  • 7.6. Immunosuppressive Agents
  • 7.7. PDE-5 Inhibitors
  • 7.8. Prostacyclin Analogues

8. Scleroderma Diagnostics & Therapeutics Market, by Therapeutics

  • 8.1. Introduction
  • 8.2. Biologic Therapies
  • 8.3. Gene Therapy
  • 8.4. Pulmonary Fibrosis Treatments
  • 8.5. Raynaud's Phenomenon Management
  • 8.6. Stem Cell Transplantation

9. Scleroderma Diagnostics & Therapeutics Market, by Indication

  • 9.1. Introduction
  • 9.2. Localized
  • 9.3. Systemic

10. Americas Scleroderma Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Scleroderma Diagnostics & Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. AbbVie Inc.
    • 14.1.2. Amgen Inc.
    • 14.1.3. Antibodies Inc.
    • 14.1.4. AstraZeneca plc
    • 14.1.5. Bayer AG
    • 14.1.6. Bio-Rad Laboratories, Inc
    • 14.1.7. Biogen Inc.
    • 14.1.8. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 14.1.9. Eli Lilly and Company
    • 14.1.10. Exagen Inc.
    • 14.1.11. F. Hoffmann-La Roche Ltd.
    • 14.1.12. Galapagos NV
    • 14.1.13. Gilead Sciences, Inc.
    • 14.1.14. GlaxoSmithKline plc (GSK)
    • 14.1.15. Merck & Co., Inc.
    • 14.1.16. Myriad Genetics, Inc
    • 14.1.17. Novartis AG
    • 14.1.18. PerkinElmer Inc.
    • 14.1.19. Pfizer Inc.
    • 14.1.20. Regeneron Pharmaceuticals, Inc.
    • 14.1.21. Sanofi Genzyme
    • 14.1.22. Takeda Pharmaceutical Company Limited
    • 14.1.23. The Bristol-Myers Squibb Company
    • 14.1.24. Thermo Fisher Scientific Inc.
    • 14.1.25. Trinity Biotech plc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 8. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 12. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 9. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CT SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHELATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ENDOTHELIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PDE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTACYCLIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RAYNAUD'S PHENOMENON MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET LICENSE & PRICING